Sermorelin: HGH / Somatropin research guide

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the active fragment of growth-hormone-releasing hormone (GHRH 1-29). It signals the pituitary to release its own growth hormone. It is supplied as a lyophilised research-grade powder for laboratory use only.

In research models sermorelin binds the pituitary GHRH receptor and prompts a natural, pulse-like release of growth hormone (and downstream IGF-1), rather than supplying GH directly. These are findings in research models; New-U supplies it for laboratory research only and implies no human therapeutic effect.

Sermorelin is a well-characterised GHRH analogue and reliably stimulates pituitary GH release in published studies, which is why it is so widely researched. Effectiveness for any human outcome is a separate, medically-supervised question outside our scope — it is sold strictly as a research compound.

In the research literature sermorelin is used as a tool compound to study the GH/IGF-1 axis, pituitary function and body-composition endpoints, often paired with a ghrelin-receptor agonist such as ipamorelin. New-U supplies it strictly for in-vitro and animal-model research; it is not for human use.

Sermorelin has a long research and (historically) clinical record as a GHRH analogue, but research-grade material is not an approved sterile medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.

Sermorelin was historically FDA-approved (as Geref) but that branded product was discontinued; it is no longer marketed as an approved drug, though it remains available through compounding pharmacies by prescription. New-U's sermorelin is research-grade material supplied for laboratory research only — not an approved medicine and not for human use.

HGH is the finished hormone and directly activates the GH receptor on every tissue. Sermorelin works one step upstream - it tells the pituitary to secrete its own GH in a physiologic pulse, preserving somatostatin feedback. That generally produces a more natural release pattern but a lower peak than direct HGH dosing.

The body naturally releases most of its GH during early deep sleep via a hypothalamic GHRH pulse. Evening dosing of sermorelin aligns the induced pulse with this natural rhythm, amplifying the physiologic nocturnal surge rather than creating a new one at an unusual time.

Yes - combining a GHRH analog with a ghrelin-receptor agonist is a common research pairing. The two mechanisms are complementary (GHRHR plus GHSR), and the combined GH release is larger than either peptide alone in published studies.

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Sermorelin is relatively stable once reconstituted but should be used within the standard peptide-stability window.

In the clinical and preclinical literature, sermorelin-induced GH release has been studied for downstream effects on the GH/IGF-1 axis - body composition, sleep architecture, recovery markers and IGF-1 elevation - while preserving the pituitary's own somatostatin feedback. These are research findings; sermorelin is not sold for human use and New-U makes no therapeutic claims.

Published research and the historical clinical record (sermorelin was once marketed as Geref) describe microgram-to-low-milligram subcutaneous amounts once daily, typically at night to match the natural nocturnal GH pulse. New-U publishes this only as descriptive research context - it is not a dosing instruction, and sermorelin is supplied strictly for laboratory research, not human use.

The research and historical clinical literature most commonly note injection-site reactions (redness, swelling), occasional flushing, headache or transient dizziness; serious effects are uncommon at the amounts studied because the pituitary's own feedback caps GH output. This is summarised research context, not medical advice - sermorelin is a research compound, not an approved medicine.

Sermorelin is a GHRH analogue (it acts on the GHRH receptor); ipamorelin is a selective ghrelin-receptor (GHSR) agonist. They drive growth-hormone release through two different receptors, which is why they are frequently co-studied as a complementary pair. See our Ipamorelin vs Sermorelin research comparison for the full mechanism-by-mechanism breakdown.

IGF-1 and GH-pulse changes are measurable within days to weeks in study settings, while body-composition and sleep endpoints are typically assessed over 8-24 weeks of continued research dosing. Timelines depend entirely on the protocol and endpoint measured. Reported for research context only - not a human-use claim.

Sermorelin and other GHRH-analogue research peptides act by prompting the pituitary to release its own growth hormone rather than supplying hormone directly, so the published literature describes the GH/IGF-1 axis returning toward its pre-treatment baseline once stimulation ends — without the shutdown associated with stopping exogenous HGH. Any effects seen in a study fade as the short-acting peptide clears. These are research observations; sermorelin is supplied for laboratory research only and is not for human use.

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.